Adaptimmune Therapeutics Plc (ADAP) Insider Trading
- $80,274,368.40
- $25,103,008.32
- Jan. 16, 2024
- Adrian Rawcliffe
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| June 9, 2020 | Director | 12,900 | $1.89 | Buy | $24,381.00 | |
| May 29, 2020 | Director | 500,000 | $9.33 | Sell | $4,665,000.00 | |
| Jan. 24, 2020 | Major Shareholder | 7,500,000 | $0.67 | Buy | $5,025,000.00 | |
| Jan. 14, 2020 | COO | 2,397 | $5.13 | Sell | $12,296.61 | |
| Jan. 14, 2020 | CEO | 3,236 | $5.13 | Sell | $16,600.68 | |
| Jan. 14, 2020 | Insider | 911 | $5.13 | Sell | $4,673.43 | |
| Jan. 13, 2020 | Director | 300,000 | $4.67 | Sell | $1,401,000.00 | |
| Jan. 6, 2020 | Insider | 1,148 | $1.20 | Sell | $1,377.60 | |
| Jan. 6, 2020 | COO | 3,731 | $1.20 | Sell | $4,477.20 | |
| Jan. 6, 2020 | CEO | 5,900 | $1.20 | Sell | $7,080.00 | |
| Aug. 6, 2019 | Insider | 11,043 | $2.06 | Sell | $22,748.58 | |
| Jan. 14, 2019 | Insider | 3,028 | $5.37 | Sell | $16,260.36 | |
| Jan. 14, 2019 | CFO | 3,084 | $5.37 | Sell | $16,561.08 | |
| Jan. 14, 2019 | CTO | 1,514 | $5.37 | Sell | $8,130.18 | |
| Jan. 14, 2019 | COO | 2,271 | $5.37 | Sell | $12,195.27 | |
| Dec. 17, 2018 | Director | 47,280 | $0.84 | Buy | $39,715.20 | |
| Oct. 1, 2018 | Insider | 25,000 | $13.79 | Sell | $344,750.00 | |
| Sept. 7, 2018 | Director | 12,000,000 | $1.67 | Buy | $20,040,000.00 | |
| Sept. 7, 2018 | Major Shareholder | 3,000,000 | $1.67 | Buy | $5,010,000.00 | |
| Aug. 29, 2018 | Insider | 25,000 | $10.25 | Sell | $256,250.00 | |
| June 6, 2018 | Director | 18,700 | $13.56 | Sell | $253,572.00 | |
| June 4, 2018 | Director | 17,100 | $13.57 | Sell | $232,047.00 | |
| June 1, 2018 | Director | 171,000 | $13.51 | Sell | $2,310,210.00 | |
| May 30, 2018 | Director | 121,000 | $13.52 | Sell | $1,635,920.00 | |
| May 14, 2018 | Director | 10,300 | $13.50 | Sell | $139,050.00 | |
| March 29, 2018 | Director | 1,048,067 | $11.50 | Sell | $12,052,770.50 | |
| March 27, 2018 | Major Shareholder | 6,571,164 | $1.92 | Buy | $12,616,634.88 | |
| March 26, 2018 | Director | 571,164 | $1.90 | Buy | $1,085,211.60 | |
| March 23, 2018 | Major Shareholder | 1,268,508 | $1.91 | Buy | $2,422,850.28 | |
| March 22, 2018 | Director | 869,574 | $1.90 | Buy | $1,652,190.60 | |
| March 21, 2018 | Major Shareholder | 104,844 | $1.81 | Buy | $189,767.64 | |
| March 20, 2018 | CFO | 600,000 | $1.71 | Sell | $1,026,000.00 | |
| March 27, 2017 | Director | 1,190,476 | $4.20 | Buy | $4,999,999.20 | |
| March 27, 2017 | Major Shareholder | 12,870,000 | $0.70 | Buy | $9,009,000.00 | |
| May 24, 2016 | Director | 1,712,400 | $10.42 | Buy | $17,843,208.00 | |
| May 19, 2016 | Director | 15,000 | $1.56 | Buy | $23,400.00 | |
| May 18, 2016 | Director | 45,000 | $1.53 | Buy | $68,850.00 |
Insiders are both buying and selling Adaptimmune Therapeutics Plc stock.
The insider traders at Adaptimmune Therapeutics Plc are: Adrian Rawcliffe, John Lunger, William C Bertrand Jr, William C. Bertrand, Jr., Elliot Norry, Orbimed Advisors Llc, Enterprise Associates 14 New, Peter A Thompson, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, David M Mott, James Noble, Lawrence M. Alleva, Rafael Amado, Charles Elliott Sigal, Peter W Sonsini, Ali Behbahani, Ravi Viswanathan, Cintia Piccina, and Garry E Menzel
The most active insider trader at Adaptimmune Therapeutics Plc is Adrian Rawcliffe with 23 trades.
Orbimed Advisors Llc has sold the most Adaptimmune Therapeutics Plc stock with a total value of $14,870,124.50.
Ali Behbahani has bought the most Adaptimmune Therapeutics Plc stock with a total value of $40,080,000.00.
The most recent insider trade for Adaptimmune Therapeutics Plc was on Jan. 16, 2024.
The single biggest insider buy for Adaptimmune Therapeutics Plc was from Ali Behbahani with a total value of $20,040,000.00 on Sept. 7, 2018.
The single biggest insider sell for Adaptimmune Therapeutics Plc was from Orbimed Advisors Llc with a total value of $12,052,770.50 on March 29, 2018.